An Open-label, Randomized, Phase 2, Parallel, Dose-ranging, Multicenter Study of Sotatercept for the Treatment of Patients With Anemia and Low- or Intermediate-1 Risk Myelodysplastic Syndromes or Non-proliferative Chronic Myelomonocytic Leukemia (CMML).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Sotatercept (Primary)
- Indications Anaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celgene Corporation
- 02 Mar 2018 Planned End Date changed from 24 Jul 2018 to 20 Apr 2018.
- 02 Mar 2018 Planned primary completion date changed from 1 Jun 2016 to 20 Apr 2018.
- 01 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Jul 2018.